drugset / Trial / NCT00281125
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2). This study is designed to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of PTK787 when administered in combination with Pemetrexed or Pemetrexed and Cisplatin, and to characterize the safety, tolerability, biologic activity, and PK profile of PTK787 in adult patients with advanced non-small cell lung cancers and mesotheliomas.
Timeline
- Start
- 2006-01
- Primary completion
- 2006-09
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | vatalanib | Small molecule | 750 mg | Oral |
| Background | Pemetrexed | Small molecule | — | — |